Prevalence of Pre-antiretroviral-Treatment Drug Resistance by Gender, Age, and Other Factors in HIV-Infected Individuals Initiating Therapy in Kenya, 2013-2014.
PMID: 29040633
2017
The Journal of infectious diseases
Abstract: PDR was defined as >=2% mutant frequency in a participant's HIV quasispecies at pol codons K103N, Y181C, G190A, M184 V, or K65R by oligonucleotide ligation assay and Illumina sequencing.
Upward trends of acquired drug resistances in Ethiopian HIV-1C isolates: A decade longitudinal study.
Abstract: The most frequent NNRTIs associated mutations were K103N, V106M and Y188C.
Result: Among the virological failed patients only one patient had K103N mutation which confers resistance to NNRTIs.
Result: At T1, the NNRTIs resistance associated mutations were detected at a lower frequency [K103N (n = 2), V106M, Y181S, Y188L, V90I, K101E and G190A (n = 1 each)].
Table: K103N
Discussion: Lastly, the study in one side identified
Dynamic HIV-1 genetic recombination and genotypic drug resistance among treatment-experienced adults in northern Ghana.
PMID: 29068286
2017
Journal of medical microbiology
Abstract: The most frequent mutations were lamivudine-resistance M184V and efavirenz/nevirapine-resistance K103N.
Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaounde, Cameroon.
Abstract: Overall, 7.3% transmitted and 34.3% acquired DRMs were found, including M184V, thymidine analogue mutations (T215F, D67N, K70R, K219Q), NNRTIs (L100I, Y181C, K103N, V108I, Y188L), and PIs (V82L).
Method: Analysis of pol sequences showed that 11 of these 32 subjects (34.3%) were infected with viruses harboring major DRMs, including major resistance mutations to NRTIs such as D67N, K70R
Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N'Djamena, Chad: findings from a cross-sectional study.
Abstract: Overall, 32% (37/116) patients presented >= one major drug resistant mutation(s), with 29% (34/116) to nucleos(t)ide reverse transcriptase inhibitors (67% [29/43] M184V/I, 30% [13/43] T215Y/F, 19% [8/43] V75A/F/I/L/M, 9% [4/43] K70P/R/W, 9% [4/43] K219E/N/Q and 5% [2/43] A62V); 86% (37/43) to non-nulceos(t)ide reverse transcriptase inhibitors (30% [13/43] K103N/S/E, 26% [11/43] Y181C/V/F/L, 2% [1/43] L100I, 2% [1/43] F227L, 2% [1/43] P225H); and 2% (1/43
[Drug resistance mutations and its associated factors among 579 HIV/AIDS patients experiencing failure of antiretroviral therapy in Jiangsu Province, China].
PMID: 29136743
2017
Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
Abstract: M184V/I and K103N/Q were the highest frequency of NRTI and NNRTI resistance mutation, the prevalence of M184V/I and K103N/Q were 28.15% and 22.28%, respectively.
Transmission Dynamics of HIV-1 Drug Resistance among Treatment-Naive Individuals in Greece: The Added Value of Molecular Epidemiology to Public Health.
Abstract: K103N and E138A_4 showed similar characteristics with a more recent origin, higher Re during the first years of the sub-epidemics, and a declining trend in the number of transmissions during the last two years.
Abstract: For the K103N LTN, the Re was >1 between 2008 and the first half of 2013.
Abstract: We analyzed sequences with dominant NNRTI resistance mutations (E138A and K103N) found within monophyletic clusters (local transmission networks (LTNs)) from patients in Greece.
Introduction: Resistance to NNRTIs was the most prevalent (16.9%), and our previous analysis revealed that the majority (89%) of NNRTI-resistant viruses (E138A,
Discovery of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP.
Abstract: Notably, both compounds showed potent antiviral activity against K103N (EC50 = 0.032 and 0.070 muM) and E138K (EC50 = 0.035 and 0.045 muM, respectively).
HIV-1 viraemia and drug resistance amongst female sex workers in Soweto, South Africa: A cross sectional study.
Result: Amongst treatment defaulters (n = 5), 4 had the K103N mutation and 1 had the V106M mutation.
Result: Amongst treatment naive FSWs, 20 had the NNRTI mutations K103N, 4 had the K101E or V106E mutations.
Result: For those on treatment (n = 14), 7 had the K103N mutations and 5 had the V106M or G190A mutations, and 2 and the K101E mutations.
Result: Overall, the number of FSWs with the K103N mutation was 68.9% (31/45), the K101E mutation was found in 6/45 (13.3%), the V106M mutation in 10/45 (22.2%), PMID: 26016726
2016
International journal of STD & AIDS
Abstract: The antiretroviral class with the most common major mutation was the non-nucleoside reverse transcriptase inhibitors (NNRTIs) where K103N was the most common major NNRTI mutation at presentation.
HIV mutation literature information.
PMID: 
2017
The Journal of infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT